These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

815 related items for PubMed ID: 29599413

  • 1. Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models.
    Saha D, Wakimoto H, Peters CW, Antoszczyk SJ, Rabkin SD, Martuza RL.
    Clin Cancer Res; 2018 Jul 15; 24(14):3409-3422. PubMed ID: 29599413
    [Abstract] [Full Text] [Related]

  • 2. Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models.
    Esaki S, Nigim F, Moon E, Luk S, Kiyokawa J, Curry W, Cahill DP, Chi AS, Iafrate AJ, Martuza RL, Rabkin SD, Wakimoto H.
    Int J Cancer; 2017 Dec 01; 141(11):2348-2358. PubMed ID: 28801914
    [Abstract] [Full Text] [Related]

  • 3. Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts.
    Cheema TA, Kanai R, Kim GW, Wakimoto H, Passer B, Rabkin SD, Martuza RL.
    Clin Cancer Res; 2011 Dec 01; 17(23):7383-93. PubMed ID: 21976549
    [Abstract] [Full Text] [Related]

  • 4. Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells.
    Sgubin D, Wakimoto H, Kanai R, Rabkin SD, Martuza RL.
    Stem Cells Transl Med; 2012 Apr 01; 1(4):322-32. PubMed ID: 23197811
    [Abstract] [Full Text] [Related]

  • 5. Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma.
    Saha D, Rabkin SD, Martuza RL.
    J Immunother Cancer; 2020 May 01; 8(1):. PubMed ID: 32457126
    [Abstract] [Full Text] [Related]

  • 6. Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models.
    Zhang W, Fulci G, Wakimoto H, Cheema TA, Buhrman JS, Jeyaretna DS, Stemmer Rachamimov AO, Rabkin SD, Martuza RL.
    Neoplasia; 2013 Jun 01; 15(6):591-9. PubMed ID: 23730207
    [Abstract] [Full Text] [Related]

  • 7. Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival.
    Bommareddy PK, Wakimoto H, Martuza RL, Kaufman HL, Rabkin SD, Saha D.
    J Immunother Cancer; 2024 Apr 09; 12(4):. PubMed ID: 38599661
    [Abstract] [Full Text] [Related]

  • 8. Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model.
    Cheema TA, Wakimoto H, Fecci PE, Ning J, Kuroda T, Jeyaretna DS, Martuza RL, Rabkin SD.
    Proc Natl Acad Sci U S A; 2013 Jul 16; 110(29):12006-11. PubMed ID: 23754388
    [Abstract] [Full Text] [Related]

  • 9. Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma.
    Lu L, Saha D, Martuza RL, Rabkin SD, Wakimoto H.
    J Neurooncol; 2015 Jan 16; 121(1):91-100. PubMed ID: 25213669
    [Abstract] [Full Text] [Related]

  • 10. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
    Ning J, Wakimoto H, Peters C, Martuza RL, Rabkin SD.
    J Natl Cancer Inst; 2017 Mar 01; 109(3):1-13. PubMed ID: 28376211
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma.
    Nakashima H, Nguyen T, Kasai K, Passaro C, Ito H, Goins WF, Shaikh I, Erdelyi R, Nishihara R, Nakano I, Reardon DA, Anderson AC, Kuchroo V, Chiocca EA.
    Clin Cancer Res; 2018 Jun 01; 24(11):2574-2584. PubMed ID: 29511029
    [Abstract] [Full Text] [Related]

  • 13. Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade.
    Saha D, Martuza RL, Rabkin SD.
    Cancer Cell; 2017 Aug 14; 32(2):253-267.e5. PubMed ID: 28810147
    [Abstract] [Full Text] [Related]

  • 14. A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells.
    Kanai R, Wakimoto H, Martuza RL, Rabkin SD.
    Clin Cancer Res; 2011 Jun 01; 17(11):3686-96. PubMed ID: 21505062
    [Abstract] [Full Text] [Related]

  • 15. Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy.
    Passaro C, Alayo Q, De Laura I, McNulty J, Grauwet K, Ito H, Bhaskaran V, Mineo M, Lawler SE, Shah K, Speranza MC, Goins W, McLaughlin E, Fernandez S, Reardon DA, Freeman GJ, Chiocca EA, Nakashima H.
    Clin Cancer Res; 2019 Jan 01; 25(1):290-299. PubMed ID: 30279232
    [Abstract] [Full Text] [Related]

  • 16. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.
    Wakimoto H, Kesari S, Farrell CJ, Curry WT, Zaupa C, Aghi M, Kuroda T, Stemmer-Rachamimov A, Shah K, Liu TC, Jeyaretna DS, Debasitis J, Pruszak J, Martuza RL, Rabkin SD.
    Cancer Res; 2009 Apr 15; 69(8):3472-81. PubMed ID: 19351838
    [Abstract] [Full Text] [Related]

  • 17. Treatment of Human Glioblastoma with a Live Attenuated Zika Virus Vaccine Candidate.
    Chen Q, Wu J, Ye Q, Ma F, Zhu Q, Wu Y, Shan C, Xie X, Li D, Zhan X, Li C, Li XF, Qin X, Zhao T, Wu H, Shi PY, Man J, Qin CF.
    mBio; 2018 Sep 18; 9(5):. PubMed ID: 30228241
    [Abstract] [Full Text] [Related]

  • 18. Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cells.
    Kardani K, Sanchez Gil J, Rabkin SD.
    Front Cell Infect Microbiol; 2023 Sep 18; 13():1206111. PubMed ID: 37325516
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma.
    Saha D, Martuza RL, Rabkin SD.
    Immunotherapy; 2018 Jul 18; 10(9):779-786. PubMed ID: 30008259
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.